Featured Research

from universities, journals, and other organizations

Psoriatic Arthritis Treatment of Ustekinumab Effective, Study Suggests

Date:
February 22, 2009
Source:
Tufts University, Health Sciences
Summary:
A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriatic arthritis.

A group of patients suffering from potentially debilitating psoriatic arthritis showed significant and prolonged improvement after treatment with ustekinumab, according to data from a randomized, double-blind, placebo-controlled study in patients with moderate to severe psoriatic arthritis (PsA). The Phase 2 study was published in the British medical journal The Lancet.

Related Articles


"This is a positive development for patients living with the joint pain and swelling that characterizes the disease, even as more research is needed to further test the efficacy of this treatment in psoriatic arthritis," said Alice Gottlieb, MD, Chairperson of the Department of Dermatology at Tufts Medical Center and lead author of the study.

Tufts Medical Center was among several academic medical centers which participated in the study. Tufts Medical Center is a 451-bed hospital in Boston and the primary teaching hospital for Tufts University School of Medicine.

Ustekinumab is a human immunoglobulin monoclonal antibody that is also being studied for treatment of patients with moderate-to-severe plaque psoriasis. Researchers conducting the study published in The Lancet reported that at week 12 of the study, 42 percent of patients given 63 or 90 mg of the drug at weeks 0, 1, 2 and 3 showed significant improvement in their pain, stiffness and other symptoms defined by the American College of Rheumatology (ACR20) score compared with 14 percent of patients who received placebo at the same time points (P < 0.001). At week 36, 33 weeks after their last dose, approximately three quarters of patients who had achieved ACR 20 sustained the improvement in their psoriatic arthritis symptoms. Also at week 24, 12 weeks after their initial ustekinumab dose, 51 percent of patients who had initially received placebo at Weeks 0, 1, 2 and 3 achieved ACR 20 following two doses of ustekinumab at weeks 12 and 16.

A secondary endpoint of the study showed that of patients who had plaque psoriasis on at least 3 percent of their body, 52 percent receiving 63 or 90 mg ustekinumab at weeks 0, 1, 2 and 3 achieved at least a 75 percent improvement in psoriasis from baseline as measured by the Psoriasis Area and Severity Index (PASI 75) at week 12 compared with five percent of patients receiving placebo (P < 0.001).

Through week 12, the placebo-controlled portion of the study, the proportion of patients with at least one adverse event (AE) was similar between patients in Group 1 receiving ustekinumab (61 percent) and those in Group 2 receiving placebo (63 percent). There were no serious AEs in Group 1 versus 4 percent of patients (n=3) in Group 2. There were no deaths, no reports of malignancy, tuberculosis or serious infections in either group. Through week 36, after the placebo crossover, the pattern of AEs was similar to that observed through week 12 of the trial.


Story Source:

The above story is based on materials provided by Tufts University, Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

Tufts University, Health Sciences. "Psoriatic Arthritis Treatment of Ustekinumab Effective, Study Suggests." ScienceDaily. ScienceDaily, 22 February 2009. <www.sciencedaily.com/releases/2009/02/090211193813.htm>.
Tufts University, Health Sciences. (2009, February 22). Psoriatic Arthritis Treatment of Ustekinumab Effective, Study Suggests. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2009/02/090211193813.htm
Tufts University, Health Sciences. "Psoriatic Arthritis Treatment of Ustekinumab Effective, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/02/090211193813.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins